Mr Liu Jianshun, Chairman of Zhangzhou Pien Tze Huang Pharmaceutical Company Limited (front row, second from left) and Professor Albert Chan (front row, third from left) pose for a photo with representatives of the two parties after the signing of the agreement


漳州片仔癀藥業股份有限公司董事長劉建順(前排左二)與陳新滋校長(前排左三)與雙方代表在簽署合作協議後合照

Date: 22 Apr 2015 (Wednesday)

Archive

HKBU collaborates with Mainland pharmaceutical company to establish joint innovative research platform for Chinese medicines

浸大與內地藥廠共建中藥創新研發平台

HKBU signed an agreement with Zhangzhou Pien Tze Huang Pharmaceutical Company Limited today (22 April) to establish a joint innovative research platform for Chinese medicines.  By integrating their technologies and cooperation network, the two parties aim to conduct innovative research on Chinese medicines. Together, they plan to build a modern, multi-disciplinary centre for innovative research into Chinese medicines with wide application prospects that meet international advanced standards. The centre will also serve as a think tank for the two parties in the research and development of new drugs and health products, such as health food products.  

The Company plans to provide research funding of HK$5 million, while the School of Chinese Medicine will contribute knowledge and technologies. The two parties will join hands to conduct innovative research on Chinese medicines, submit joint applications for government research grants and provide researchers with secondment opportunities. Planned collaborations include the study on proprietary Chinese medicines including the “Pien Tze Huang” treatment for chronic inflammatory conditions, development of health food products, and studies into the efficacy, composition, preparation and mechanism of other products of the Company with a view to developing new and improved drugs.  

Professor Albert Chan, President and Vice-Chancellor, said Zhangzhou Pien Tze Huang is a leading pharmaceutical enterprise in Mainland China whose products are held in high regard both at home and overseas, and the School of Chinese Medicine has built up considerable strength in discovering new Chinese herbal drugs. As a result, the collaboration will enhance the strengths of the two parties and benefit the Chinese medicines industry in the region as well as public health.

浸會大學與漳州片仔癀藥業股份有限公司於今日(422日)簽署合作協議,共建一個中藥創新研發平台,期望通過整合雙方的科技資源和合作網絡,共同進行中藥創新研究,建成具有廣泛應用前景和國際先進水準的現代化跨學科中藥創新研究中心,並在雙方的新藥、保健食品等健康產品合作研發上擔當智庫。  

漳州片仔癀計劃於三年內提供500萬港元的研究經費,而浸大中醫藥學院則提供研發技術。雙方將共同開展中藥創新研究、聯合申請政府資助研究經費、安排研究人員互訪交流。目前計劃的合作項目包括開展以中成藥「片仔癀」治療慢性炎症的研究、開發保健食品,以及對該公司的其他藥物進行療效、成分、作用機理、制劑或安全等方面的研究,務求開發更高技術的新藥品種。  

校長陳新滋教授說,漳州片仔癀居全國中成藥行業前列,研製的中藥產品深受海內外人士歡迎,浸大中醫藥學院則在中藥創新藥物研發實力雄厚,雙方的合作能夠加強各自的優勢,為區域內的中醫藥產業發展和大眾健康作出貢獻。